Reviewing Alpha Cognition (ACOG) & The Competition

Alpha Cognition (NASDAQ:ACOG) is one of 300 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare Alpha Cognition to related companies based on the strength of its dividends, institutional ownership, valuation, profitability, risk, analyst recommendations and earnings.

Earnings and Valuation

This table compares Alpha Cognition and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Alpha Cognition	N/A	-$13.77 million	-2.41
Alpha Cognition Competitors	$575.27 million	-$70.96 million	0.21

Alpha Cognition’s rivals have higher revenue, but lower earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Alpha Cognition has a beta of 2.5, indicating that its share price is 150% more volatile than the S&P 500. Comparatively, Alpha Cognition’s rivals have a beta of -4.48, indicating that their average share price is 548% less volatile than the S&P 500.

Insider & Institutional Ownership

50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 31.5% of Alpha Cognition shares are owned by insiders. Comparatively, 15.7% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Alpha Cognition and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	N/A	N/A	-344.17%
Alpha Cognition Competitors	-2,185.76%	-161.46%	-40.62%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Alpha Cognition and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0	0	1	0	3.00
Alpha Cognition Competitors	1946	5412	13998	300	2.58

Alpha Cognition currently has a consensus price target of $20.00, suggesting a potential upside of 356.62%. As a group, “Biological products, except diagnostic” companies have a potential upside of 119.33%. Given Alpha Cognition’s stronger consensus rating and higher possible upside, research analysts plainly believe Alpha Cognition is more favorable than its rivals.

Summary

Alpha Cognition beats its rivals on 8 of the 13 factors compared.

Alpha Cognition Company Profile

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.